Synovics Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYVC research report →
About the company
Synovics Pharmaceuticals, Inc. , through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company’s OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives.
- CEO
- Christopher J. Flynn
- IPO
- 2004
- Employees
- 155
- HQ
- Fort Lauderdale, FL, US
Price Chart
- Market Cap
- $2.98K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -3.47
- Div Yield
- 0.00%
- Gross Margin
- 34.56%
- Op Margin
- -9.57%
- Net Margin
- -15.43%
- ROE
- 258.22%
- ROIC
- -21.49%
- Revenue
- $25.96M · 10.62%
- Net Income
- $-4,005,831 · 80.79%
- EPS
- $-0.17 · 84.40%
- Op Income
- $-2,483,465
- FCF YoY
- 171.80%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 169.69
- Avg Volume
- 236
Get TickerSpark's AI analysis on SYVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SYVC coverage
Recent articles, reports, and earnings notes.
No research on SYVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYVC report →Similar companies
Peers in the same neighborhood.